The Company and Basis of Presentation (Details) $ / shares in Units, $ in Thousands					1 Months Ended	12 Months Ended
	Jan. 18, 2024 USD ($) $ / shares shares	Jan. 02, 2024 USD ($)	Mar. 22, 2023 USD ($) $ / shares shares	Mar. 19, 2023 USD ($) $ / shares shares	Aug. 31, 2019 patient	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2020 product	Mar. 23, 2023 $ / shares	Dec. 31, 2021 $ / shares
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Products approved | product								2
Number of study patients | patient					14,000
Common stock, shares issued (in shares) | shares						120,204,513	76,564,396
Common stock, par value (in dollars per share)						$ 0.001	$ 0.001
Proceeds from issuance of common stock, net of issuance costs | $						$ 4,448	$ 90,849
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Net proceeds | $	$ 90,800
First milestone payment | $		$ 100,000
Time required to pay cash portion		15 days
Second milestone payment | $		$ 25,000
Subsequent Event | Minimum
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Aggregate payment agreement | $		$ 125,000
Underwritten Public Offering | Subsequent Event
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Exercise price (in dollars per share)	$ 1.50
Net proceeds | $	$ 90,800
Issued stock (in shares) | shares	56,700,000
Price per share (in dollars per share)	$ 1.50
Over Allotment Option | Subsequent Event
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Issued stock (in shares) | shares	8,505,000
Option period	30 days
Securities Purchase Agreement
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock, shares issued (in shares) | shares				12,205,000
Common stock, par value (in dollars per share)				$ 0.001
Common stock purchasable under prefunded warrants (in shares) | shares				20,965,747
Common stock purchasable under warrants (in shares) | shares				33,170,747
Exercise price (in dollars per share)						$ 1.55
Securities Purchase Agreement | Common Stock And Accompanying Warrant
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Purchase price (in dollars per share)				$ 1.675
Securities Purchase Agreement | Pre Funded Warrant And Accompanying Warrant
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Purchase price (in dollars per share)				$ 1.674
Warrant Amendment Agreements
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock purchasable under warrants (in shares) | shares			9,024,212
Exercise price (in dollars per share)			$ 1.55			$ 1.55			$ 1.55	$ 9.00
Expiration term									3 years 6 months
Additional consideration (in dollars per share)			$ 0.125
Net proceeds | $			$ 55,500	$ 1,200
Proceeds from issuance of common stock, net of issuance costs | $				$ 51,300
Proceeds from warrant amendment | $			$ 1,100